SUPERNOVA, an RCT of sipavibart vs evushield/placebo to prevent Covid in >3300 immunocompromised
Sipavibart assoc w fewer symptomatic Covid infxns at 6mo (NNT 29). No dif in severe dz (not powered for this). No efficacy vs Phe456Leu-containing variants eg XBB
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00804-1/fulltext
Sipavibart assoc w fewer symptomatic Covid infxns at 6mo (NNT 29). No dif in severe dz (not powered for this). No efficacy vs Phe456Leu-containing variants eg XBB
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00804-1/fulltext
Comments
Severe Covid outcomes are now rare, even in immunocompromised individuals (10 hospitalized in each arm, 1 Covid related death in comparator arm). NNT to prevent a severe (acute) outcome approaches infinity and d/t mAb whack-a-mole this approach is unsustainable
#idsky #txid